Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis
Author:
Funder
Winship Cancer Institute
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference34 articles.
1. Cancer statistics, 2020;Siegel;Ca - Cancer J. Clin.,2020
2. Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer;Carlisle;Future Oncol.,2019
3. Emerging treatment paradigms for EGFR-mutant lung cancers progressing on osimertinib: a review;Piper-Vallillo;J. Clin. Oncol.,2020
4. MEK5/ERK5 pathway: the first fifteen years;Drew;Biochim. Biophys. Acta,2012
5. Components of a new human protein kinase signal transduction pathway;Zhou;J. Biol. Chem.,1995
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression;Neoplasia;2023-08
2. Case report: Long-term survival with anlotinib in a metastatic parathyroid carcinoma patient harboring EGFR-sensitizing mutation;2023-07-10
3. Cooperation between Prostaglandin E2 and Epidermal Growth Factor Receptor in Cancer Progression: A Dual Target for Cancer Therapy;Cancers;2023-04-19
4. MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells;Cancer Research Communications;2023-01-30
5. Design, Synthesis and in Vitro Antitumor Evaluation of EGFR-Targeting Small Molecule Degraders;2023
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3